Loading clinical trials...
Loading clinical trials...
A Real-world Study of Consolidation Durvalumab for Stage III Unresectable Non-small Cell Lung Cancer in China and Safety Data on Durvalumab in Chinese Patients With Lung Cancer（PACIFIC-PUMCH-R）
Conditions
Interventions
Durvalumab
Durvalumab
Locations
1
China
Peking Union Medical College Hospital
Beijing, China
Start Date
July 28, 2020
Primary Completion Date
June 1, 2021
Completion Date
October 1, 2024
Last Updated
December 17, 2020
NCT07336732
NCT06712355
NCT05419076
NCT06242470
NCT07161388
NCT07189455
Lead Sponsor
Peking Union Medical College Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions